Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis

6 years ago

by David Miller

963 Views

Written by David Miller

SAN DIEGO, December 10, 2018– Pfenex Inc. (NYSE American: PFNX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of PF708 for the treatment of osteoporosis. The…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!